Ilico Genetics, a Spin Off of Pontificia Universidad Católica de Chile, is developing the first methylated DNA based molecular test specifically designed for the early detection of gastric cancer, even years before Esophagogastroduodenoscopy (EGD, gold standard).
With only a blood sample, and even without symptoms, it detects a tumor in the stomach or lesions that could evolve to gastric cancer. The results are dynamic and show the cumulative presence of tumors over time.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 116 Research Dr,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.ilicogenetics.com
- Keywords
- liquid biopsy, gastric cancer, stomach cancer, early detection of cancer, epigenetics, medical device, SaMD, IVD.
- HQ
- Bethlehem, Pennsylvania
Ilico Genetics Questions
Ilico Genetics's website is https://www.ilicogenetics.com
Ilico Genetics's LinkedIn profile is https://www.linkedin.com/company/ilicogenetics
Ilico Genetics has
6 employees.
View email and phone details for 6
employees at Ilico Genetics.
Ilico Genetics's industry is
Biotechnology Research
Ilico Genetics's top competitors are
Synergy Therapeutics,
Orbits Oncology,
Geneos Therapeutics,
Xylocor Therapeutics, Inc.,
Basecure Therapeutics Inc.,
Thread Bioscience Inc,
Actuated Medical, Inc.,
Flamingo Therapeutics,
Biolattice,
Immunogenesis, Inc..
Ilico Genetics's categories are Biotechnology Research
Ilico Genetics's founding year is 2020
